On June 4, 2024, the Supreme Court of Russia ruled in favor of AstraZeneca (patentee) against KRKA (opponent) regarding the validity of AstraZeneca’s patent RU2746132 for «Forxiga» (INN: dapagliflozin), which is used to treat heart failure and chronic kidney disease in type 2 diabetic patients. This patent was extended by RUPTO based on «Forxiga’s» first marketing authorization, and remains valid until May 15, 2028.
This decision is obviously significant for AstraZeneca, which is currently involved in lawsuits against several generic manufacturers in Russia. Moreover, it holds substantial importance for the validity of approximately 600 other drug-related enforceable Russian patents granted on divisional applications.
By reversing the earlier IP Court decision, the Supreme Court thereby confirmed the legal correctness of RUPTO’s approach to acknowledging the priority dates of consecutive patent applications based on the first original parent application.
As a result, the divisional filing strategy at RUPTO remains as usual, maintaining a more convenient and innovator-friendly approach compared to potential alternative, which might have been appeared otherwise.
In 2025, the Eurasian patent system demonstrated steady growth in applicant activity. The number of…
The lawyers of Patentica have once again confirmed that infringement of intellectual property should not…
The World Intellectual Property Organization (WIPO) has announced the opening of applications for the WIPO…
Azerbaijan has officially launched an electronic filing service for Eurasian applications. The project was implemented…
Patentica is proud to announce that it has been honored as one of the 2025…
Anna Bobkina and Daria Orlova of Patentica participated in AIPPI MidTerm Meeting held in Red…